Human Therapeutic Antibody
ADCC-enhanced Rituximab is a non-fucosylated anti-CD20 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-CD20 Rituximab, a biobetter by reducing fucosylation of the Fc region of Rituximab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Therapeutic antibody; biobetter
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Membrane Spanning 4-Domains A1
This gene encodes a member of the membrane-spanning 4A gene family. Members of this nascent protein family are characterized by common structural features and similar intron/exon splice boundaries and display unique expression patterns among hematopoietic cells and nonlymphoid tissues. This gene encodes a B-lymphocyte surface molecule which plays a role in the development and differentiation of B-cells into plasma cells. This family member is localized to 11q12, among a cluster of family members. Alternative splicing of this gene results in two transcript variants which encode the same protein. [provided by RefSeq, Jul 2008]
MS4A1; membrane-spanning 4-domains, subfamily A, member 1; B1; S7; Bp35; CD20; CVID5; MS4A2; LEU-16; B-lymphocyte antigen CD20; CD20 antigen; CD20 receptor; leukocyte surface antigen Leu-16; B-lymphocyte cell-surface antigen B1;
Involvement in Disease
Diseases associated with MS4A1 include Immunodeficiency, Common Variable, 5 and Common Variable Immunodeficiency.
Its related pathways are Hematopoietic cell lineage and Hematopoietic Stem Cells and Lineage-specific Markers.
b lymphocyte-specific membrane protein, which is involved in the regulation of cellular calcium influx necessary for the development, differentiation and activation of b lymphocytes (PubMed:3925015, PubMed:7684739, PubMed:12920111). After activation of b-cell receptor/BCR, it acts as a component of stored and operated calcium (SOC) channels to promote calcium influx (PubMed:7684739, PubMed:12920111, PubMed:18474602).
Field of research
Cancer antibody; Developmental Biology antibody; Immune System antibody; B cell Marker antibody; Immature B Cell Marker antibody; Inflammatory Cell Marker antibody; Tumor-infiltrating Lymphocyte Study antibody
Phosphorylated. Might be functionally regulated by protein kinase(s).
Protein Based Therapies
Monoclonal antibody (mAb)
Human Therapeutic Antibody
Recombinant monoclonal antibody to Human CD20. Rituximab (trade names rituximab and rituximab) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells (this should not be confused with pancreatic β- or beta cells). Rituximab destroys B cells and is therefore used to treat diseases which are characterized by excessive numbers of B cells, overactive B cells, or dysfunctional B cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.